Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Cardiol Therapeutics Ord Shs Class A T.CRDL

Alternate Symbol(s):  CRDL | T.CRDL.W.A

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is... see more
< Previous
Next >

Current News (TSX:CRDL)

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

Newsfile 3 days ago

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Newsfile November 16, 2023

Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis

Newsfile November 1, 2023

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Newsfile October 20, 2023

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

TheNewsWire October 13, 2023

Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction

Newsfile October 10, 2023

Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference

Newsfile September 26, 2023

Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis

Newsfile September 19, 2023

Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference

Newsfile August 9, 2023

Opinion & Analysis (TSX:CRDL)

No current opinion is available.

Bullboard Posts (TSX:CRDL)

Rosewood Hotel

only 600.00 for a room fitzgerald suite is less...patrick fits gerald  and gerald ...goes home
satchmo6 - September 26, 2023

It's gonna run soon.

Technical Analysis for CRDL 1 minute1 minute5 minutes5 minutes15 minutes15 minutes30 minutes30 minutes1 hour1 hour2 hours2...
Bubula50 - June 7, 2023

Financially healthy also

Return vs Industry: CRDL exceeded the Canadian Pharmaceuticals industry which returned -55.8% over the past year.
Bubula50 - June 6, 2023

In again

You should never fall in love with stocks but Crdl is one of my faves and at this price it is a steal imo
Bubula50 - June 6, 2023

CBD Study Dr. Campbell
Bullknit101 - May 24, 2023

Cardiol Presentation - Undervalued Stock
Bullknit101 - February 25, 2023